Multiple Myeloma, Phase II
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Volunteers
Health Professionals
What is the purpose of this trial?
The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants with RRMM having received 1 to 3 prior lines of therapy.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alessia Donadio, MD
- Alexis Walker
- Alfredo Axtmayer
- Andrea Brennan
- Armand Russo, MD
- Catherine Wei, MD
- Clarice Grens
- D. Barry Boyd, MD, MS
- Elan Gorshein, DO, JD, MPH
- Emily Kopas, APRN, OCN
- Erica Stevens
- Francesca Montanari, MD
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Jeremy Kortmansky, MD
- Johanna LaSala, MD
- Jose Morales-Marin
- Karishma Mehra, MBBS
- Kayla Martello
- Kelsey Martin, MD
- Kristen Hoxie
- Larisa Fleysher
- Laura Sabourin
- Leena Rahmat
- M. Sung Lee, MD
- Madeline Santiago
- Natalia Neparidze, MD
- Noffar Bar, MD
- Osarugue Otasowie
- Pawan Karanam, MD
- Sabrina Browning, MD
- Sara Anastasio, RN
- Sarah Carlson
- Stuart Seropian, MD
- Su Hsien Lim, MD
- Sudhanshu Mulay, MD
- Syed Ali
- Syed Bilgrami, MBBS
- Tara Anderson
- Terri Parker, MD
- Vidya Kesavan
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Yifei Zhang, MD
- Last Updated05/01/2025
- Study HIC#2000038338